Quiflapon

Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active Leukotriene biosynthesis (LT) inhibitor, shows IC50 values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis[1][2].

Product Specifications

CAS Number

[136668-42-3]

Product Name Alternative

MK-591

UNSPSC

12352005

Target

Apoptosis; FLAP

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/MK-0591.html

Purity

99.76

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(O)C(C)(C)CC1=C(SC(C)(C)C)C2=C(C=CC(OCC3=NC4=CC=CC=C4C=C3)=C2)N1CC5=CC=C(Cl)C=C5

Molecular Formula

C34H35ClN2O3S

Molecular Weight

587.17

References & Citations

[1]Brideau C, et al. Pharmacology of MK-0591 (3-[1- (4-chlorobenzyl) -3- (t-butylthio) -5- (quinolin-2-yl-methoxy) - indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1992 Jun;70 (6) :799-807.|[2]Park MS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung. 2011 Feb;189 (1) :43-50.